Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Coherus Oncology Inc (CHRS)

Coherus Oncology Inc (CHRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 145,045
  • Shares Outstanding, K 120,871
  • Annual Sales, $ 266,960 K
  • Annual Income, $ 28,510 K
  • EBIT $ -178 M
  • EBITDA $ -172 M
  • 60-Month Beta 0.95
  • Price/Sales 0.56
  • Price/Cash Flow 4.22
  • Price/Book 1.63

Options Overview Details

View History
  • Implied Volatility 374.57% (+24.95%)
  • Historical Volatility 83.24%
  • IV Percentile 92%
  • IV Rank 49.89%
  • IV High 670.52% on 11/17/25
  • IV Low 79.95% on 01/08/25
  • Expected Move (DTE 11) 0.2975 (24.79%)
  • Put/Call Vol Ratio 6.25
  • Today's Volume 58
  • Volume Avg (30-Day) 155
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 18,696
  • Open Int (30-Day) 19,677
  • Expected Range 0.9025 to 1.4975

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.36
  • Number of Estimates 2
  • High Estimate -0.36
  • Low Estimate -0.36
  • Prior Year -0.44
  • Growth Rate Est. (year over year) +18.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0900 +10.09%
on 11/21/25
1.6000 -25.00%
on 11/06/25
-0.3700 (-23.57%)
since 11/05/25
3-Month
1.0900 +10.09%
on 11/21/25
1.8900 -36.51%
on 10/09/25
-0.0900 (-6.98%)
since 09/05/25
52-Week
0.7100 +69.01%
on 06/23/25
1.8900 -36.51%
on 10/09/25
-0.3100 (-20.53%)
since 12/05/24

Most Recent Stories

More News
Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody

– CHS-114 demonstrated robust and selective depletion of CCR8+ Tregs as well as favorable immune remodeling in tumor tissue from head and neck squamous cell carcinoma (HNSCC) patients – – CHS-114...

CHRS : 1.2000 (-2.44%)
Coherus Oncology: Q3 Earnings Snapshot

Coherus Oncology: Q3 Earnings Snapshot

CHRS : 1.2000 (-2.44%)
Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update

– CHS-114, a highly selective Treg depleter, clinical program expanded to include colorectal cancer – – Q3 2025 ending cash, cash equivalents and marketable securities of $191.7 million –...

CHRS : 1.2000 (-2.44%)
Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer

–  Responsible for Corporate Development, Investor Relations, Government Affairs – REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced...

CHRS : 1.2000 (-2.44%)
Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025

REDWOOD CITY, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc . (Nasdaq: CHRS), today announced that its third quarter 2025 financial results will be released after market close on...

CHRS : 1.2000 (-2.44%)
Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

REDWOOD CITY, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today announced an upcoming poster presentation at the 40th Annual Meeting of the Society for Immunotherapy...

CHRS : 1.2000 (-2.44%)
Coherus Oncology to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that the company will be webcasting its participation in the following upcoming conferences:...

CHRS : 1.2000 (-2.44%)
Coherus Oncology: Q2 Earnings Snapshot

Coherus Oncology: Q2 Earnings Snapshot

CHRS : 1.2000 (-2.44%)
Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

– LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 – – Data readouts for CHS-114 and casdozokitug on track for 1H 2026 – – Q2 2025 ending cash, cash equivalents...

CHRS : 1.2000 (-2.44%)
Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc . (Coherus, Coherus Oncology or the Company, Nasdaq: CHRS), today announced that its second quarter 2025 financial results...

CHRS : 1.2000 (-2.44%)

Business Summary

Coherus is a fully integrated commercial-stage innovative oncology company. Coherus, formerly known as Coherus BioSciences Inc., is based in REDWOOD CITY, Calif.

See More

Key Turning Points

3rd Resistance Point 1.3433
2nd Resistance Point 1.3067
1st Resistance Point 1.2533
Last Price 1.2000
1st Support Level 1.1633
2nd Support Level 1.1267
3rd Support Level 1.0733

See More

52-Week High 1.8900
Fibonacci 61.8% 1.4392
Fibonacci 50% 1.3000
Last Price 1.2000
Fibonacci 38.2% 1.1608
52-Week Low 0.7100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar